Skip to main content
Top
Published in: Thrombosis Journal 1/2004

Open Access 01-12-2004 | Original clinical investigation

Relationship between CRP and hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients?

Authors: Karim Zouaoui Boudjeltia, Michael Piagnerelli, Dany Brohée, Michel Guillaume, Philippe Cauchie, Jean-Louis Vincent, Claude Remacle, Yves Bouckaert, Michel Vanhaeverbeek

Published in: Thrombosis Journal | Issue 1/2004

Login to get access

Abstract

Background-

Endothelial cell dysfunction may be implicated in the development of multiple organ failure (MOF) by a number of mechanisms. Among these, altered fibrinolysis promotes fibrin deposition, which may create microvascular alterations during inflammation. Elevated concentrations of C-reactive protein (CRP), especially when these persist over time, are correlated with an increased risk of MOF and death. CRP may inhibit fibrinolysis by inducing plasminogen activator inhibitor-1 (PAI-1) release from human aortic endothelial cells. Moreover, the administration of recombinant CRP in volunteers may increase circulating PAI-1 levels.
In this study, we tested the hypothesis that CRP is associated with hypofibrinolysis in intensive care patients with and without sepsis.

Methods-

We studied the association of inflammation and abnormal fibrinolysis in intensive care unit (ICU) patients with (n = 11) and without (n = 21) sepsis. The inflammatory response was assessed by serum concentration of C-reactive protein (CRP), a marker of the acute phase reaction, which increase rapidly in the inflammatory response, and the plasma fibrinolytic capacity was evaluated by the Euglobulin Clot Lysis Time (ECLT), determined by a new semi-automatic method.

Results-

ECLT was significantly higher in septic than non-septic patients (1104 ± 439 vs 665 ± 275 min; p = 0.002) and was significantly correlated with CRP concentration (R2 = 0.45; p < 0.001). In a multivariate analysis, CRP was the strongest predictor of ECLT (R2 = 0.51, F = 25.6, p < 0.001). In addition, the overall ICU length of stay was significantly correlated with CRP (R2 = 0.264, p = 0.003) and ECLT (R2 = 0.259, p = 0.003).

Conclusion-

In critically ill patients a significant correlation thus exists between plasma fibrinolytic capacity and serum CRP levels. Our data were obtained in the first 24 hours of ICU admission or of sepsis, thus, the relation between CRP and hypofibrinolysis appeared very quickly. This finding is compatible with a link between inflammation and abnormal fibrinolysis, and may explain the negative prognostic value of CRP in critically ill patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Levi M, ten Cate H, van der Poll T: Endothelium: interface between coagulation and inflammation. Crit Care Med. 2002, 30: S220-S224. 10.1097/00003246-200205001-00008.CrossRefPubMed Levi M, ten Cate H, van der Poll T: Endothelium: interface between coagulation and inflammation. Crit Care Med. 2002, 30: S220-S224. 10.1097/00003246-200205001-00008.CrossRefPubMed
2.
go back to reference Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003, 101: 3765-3777. 10.1182/blood-2002-06-1887.CrossRefPubMed Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003, 101: 3765-3777. 10.1182/blood-2002-06-1887.CrossRefPubMed
3.
go back to reference Idell S: Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003, 31: S213-S220. 10.1097/01.CCM.0000057846.21303.AB.CrossRefPubMed Idell S: Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003, 31: S213-S220. 10.1097/01.CCM.0000057846.21303.AB.CrossRefPubMed
4.
go back to reference Gross PL, Aird WC: The endothelium and thrombosis. Semin Thromb Hemost. 2000, 26: 463-478. 10.1055/s-2000-13202.CrossRefPubMed Gross PL, Aird WC: The endothelium and thrombosis. Semin Thromb Hemost. 2000, 26: 463-478. 10.1055/s-2000-13202.CrossRefPubMed
5.
go back to reference Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL: C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003, 123: 2043-2049. 10.1378/chest.123.6.2043.CrossRefPubMed Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL: C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003, 123: 2043-2049. 10.1378/chest.123.6.2043.CrossRefPubMed
6.
go back to reference Blann AD, Lip GY: Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis. 2003, 14: 335-340. 10.1097/00001721-200306000-00003.CrossRefPubMed Blann AD, Lip GY: Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis. 2003, 14: 335-340. 10.1097/00001721-200306000-00003.CrossRefPubMed
7.
go back to reference Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002, 105: 1890-1896. 10.1161/01.CIR.0000015126.83143.B4.CrossRefPubMed Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002, 105: 1890-1896. 10.1161/01.CIR.0000015126.83143.B4.CrossRefPubMed
8.
go back to reference Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003, 107: 398-404. 10.1161/01.CIR.0000052617.91920.FD.CrossRefPubMed Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003, 107: 398-404. 10.1161/01.CIR.0000052617.91920.FD.CrossRefPubMed
9.
go back to reference Bisoendial RJ, Kasteleuin JJ, Levels JHM, Zwaginga JJ, Van den Bogaard B, Reitsma PH, Meijers CM, Hartman D, Levi M, Stroes ESG: Activation of inflammation and Coagulation after infusion of C-reactive protein in humans. Lancet. Bisoendial RJ, Kasteleuin JJ, Levels JHM, Zwaginga JJ, Van den Bogaard B, Reitsma PH, Meijers CM, Hartman D, Levi M, Stroes ESG: Activation of inflammation and Coagulation after infusion of C-reactive protein in humans. Lancet.
10.
go back to reference Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.CrossRefPubMed Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.CrossRefPubMed
11.
go back to reference Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D: A simplified acute physiologic score for ICU patients. Crit Care Med. 1984, 12: 975-977.CrossRefPubMed Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D: A simplified acute physiologic score for ICU patients. Crit Care Med. 1984, 12: 975-977.CrossRefPubMed
12.
go back to reference Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A: Relationship netween euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1. Thrombosis Haemostasis. 1990, 63: 82-86.PubMed Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A: Relationship netween euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1. Thrombosis Haemostasis. 1990, 63: 82-86.PubMed
13.
go back to reference Boudjeltia KZ, Cauchie P, Remacle C, Guillaume M, Brohee D, Hubert JL, Vanhaeverbeek M: A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. BMC Biotechnol. 2002, 2: 8-10.1186/1472-6750-2-8.PubMedCentralCrossRefPubMed Boudjeltia KZ, Cauchie P, Remacle C, Guillaume M, Brohee D, Hubert JL, Vanhaeverbeek M: A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. BMC Biotechnol. 2002, 2: 8-10.1186/1472-6750-2-8.PubMedCentralCrossRefPubMed
14.
go back to reference Bombeli T, Mueller M, Haeberli A: Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997, 77: 408-423.PubMed Bombeli T, Mueller M, Haeberli A: Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997, 77: 408-423.PubMed
15.
go back to reference Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 2000, 98: 531-535. 10.1042/CS20000013.CrossRef Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 2000, 98: 531-535. 10.1042/CS20000013.CrossRef
16.
go back to reference Shah SH, Newby LK: C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 2003, 11: 169-179. 10.1097/01.CRD.0000077906.74217.6E.CrossRefPubMed Shah SH, Newby LK: C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 2003, 11: 169-179. 10.1097/01.CRD.0000077906.74217.6E.CrossRefPubMed
17.
go back to reference Zouaoui Boudjeltia K, Guillaume M, Kinard F, Cauchie P, Remacle C, Ducobu J, Vanhaeverbeek M, Brohee D: Effect of blood monocyte counts on plasma fibrinolytic capacity. Atherosclerosis. 2001, 2: 83 (abstract)-10.1016/S1567-5688(01)80201-4.CrossRef Zouaoui Boudjeltia K, Guillaume M, Kinard F, Cauchie P, Remacle C, Ducobu J, Vanhaeverbeek M, Brohee D: Effect of blood monocyte counts on plasma fibrinolytic capacity. Atherosclerosis. 2001, 2: 83 (abstract)-10.1016/S1567-5688(01)80201-4.CrossRef
18.
go back to reference Mesters RM, Florke N, Ostermann H, Kienast J: Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996, 75: 902-907.PubMed Mesters RM, Florke N, Ostermann H, Kienast J: Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996, 75: 902-907.PubMed
19.
go back to reference Oberhoffer M, Karzai W, Meier-Hellmann A, Bogel D, Fassbinder J, Reinhart K: Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med. 1999, 27: 1814-1818. 10.1097/00003246-199909000-00018.CrossRefPubMed Oberhoffer M, Karzai W, Meier-Hellmann A, Bogel D, Fassbinder J, Reinhart K: Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med. 1999, 27: 1814-1818. 10.1097/00003246-199909000-00018.CrossRefPubMed
20.
go back to reference Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992, 4: 361-368. 10.1016/1043-4666(92)90079-7.CrossRefPubMed Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992, 4: 361-368. 10.1016/1043-4666(92)90079-7.CrossRefPubMed
21.
go back to reference Cao H, Hegele RA: Human C-reactive protein (CRP) 1059G/C polymorphism. J Hum Genet. 2000, 45 (2): 100-1. 10.1007/s100380050022.CrossRefPubMed Cao H, Hegele RA: Human C-reactive protein (CRP) 1059G/C polymorphism. J Hum Genet. 2000, 45 (2): 100-1. 10.1007/s100380050022.CrossRefPubMed
22.
go back to reference Szalai AJ, Briles DE, Volanakis JE: Human C-reactive protein is protective against fatal streptococcus pneumoniae infection in transgenic mice. The journal of immunology. 1995, 155: 2557-2563.PubMed Szalai AJ, Briles DE, Volanakis JE: Human C-reactive protein is protective against fatal streptococcus pneumoniae infection in transgenic mice. The journal of immunology. 1995, 155: 2557-2563.PubMed
23.
go back to reference Szalai AJ, VanCott JL, McGhee JR, Volonakis JE, Benjamin WH: Human C-reactive protein is protective against fatal Salmonella enterica Serovar Typhimurium infection in Transgenic Mice. Infection and Immunity. 2000, 68 (10): 5652-5656. 10.1128/IAI.68.10.5652-5656.2000.PubMedCentralCrossRefPubMed Szalai AJ, VanCott JL, McGhee JR, Volonakis JE, Benjamin WH: Human C-reactive protein is protective against fatal Salmonella enterica Serovar Typhimurium infection in Transgenic Mice. Infection and Immunity. 2000, 68 (10): 5652-5656. 10.1128/IAI.68.10.5652-5656.2000.PubMedCentralCrossRefPubMed
Metadata
Title
Relationship between CRP and hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients?
Authors
Karim Zouaoui Boudjeltia
Michael Piagnerelli
Dany Brohée
Michel Guillaume
Philippe Cauchie
Jean-Louis Vincent
Claude Remacle
Yves Bouckaert
Michel Vanhaeverbeek
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2004
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-2-7

Other articles of this Issue 1/2004

Thrombosis Journal 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.